Brought to you by 
Cephalon acquires Anesta in $444mm stock swap
24 Jul 2000
Executive Summary
Enhancing its clinical development pipeline, Cephalon will acquire all outstanding shares of Anesta (oral transmucosal drug delivery) for $31.45 each-a (pr)32% premium--in an all-stock merger valued at $444mm or about 68 times Anesta's sales. Should Anesta withdraw from the deal, it is required to pay Cephalon a $15mm termination fee.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon acquires Anesta in $444mm stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice